We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence
← All GLP-1 drugs Drug guide

Best semaglutide programs

The most-prescribed GLP-1 for weight loss: what the trials show, and every legitimate way to get it.

What semaglutide is

A once-weekly GLP-1 receptor agonist. Sold as Wegovy (FDA-approved for chronic weight management) and Ozempic (FDA-approved for type-2 diabetes, often prescribed off-label for weight). An oral 25 mg Wegovy tablet was FDA-approved in December 2025.

The brand drug (Wegovy) is FDA-approved and dispensed through normal pharmacy channels. Compounded semaglutide is NOT FDA-approved, so weigh that route on safety and transparency, not just price.

What the trials show

In the pivotal STEP 1 trial (NEJM, 2021), semaglutide 2.4 mg produced a mean −14.9% body-weight change at 68 weeks versus −2.4% on placebo, and 86% of participants lost at least 5%. The oral 25 mg version showed about 16.6% in the OASIS 4 trial. These trials were funded by Novo Nordisk, the manufacturer.

In the head-to-head SURMOUNT-5 trial (NEJM, 2025), semaglutide produced −13.7% versus tirzepatide's −20.2% at maximum tolerated doses, so tirzepatide edged it on weight loss, though both are highly effective.

Primary sources: STEP 1 (NEJMoa2032183) · OASIS 4 · SURMOUNT-5 (NEJMoa2416394). Every figure traces to our bibliography, with manufacturer funding disclosed. This is evidence reporting, not medical advice.

Programs we recommend that offer semaglutide

The 5 programs below, out of the ones we recommend, prescribe semaglutide, shown in our methodology order. No provider pays us anything. (These are FDA-approved brand programs; for the compounded route, see the compounded comparison.)

Sort all of them by real all-in cost on the comparison page, or see the dated price index.

Will insurance cover semaglutide?

It depends on your plan and indication. Most state Medicaid programs don't cover GLP-1s for weight loss (only a handful do). Check your state. On Medicare, a federal GLP-1 "Bridge" (~$50/mo) starts July 1, 2026. If you're denied, our free appeal templates help you push back.

How we stay independent

The programs above are ranked by our 31-point methodology, and we take no money from any of them. We just filtered our ranking to the ones that offer semaglutide, never re-ordered by drug. Read what our independence costs us. Every clinical figure traces to a primary source in our bibliography; spot an error and we log the fix publicly. Not medical advice, consult a licensed clinician.

Get the monthly research digest

One plain-English email a month: new study findings, price changes, and safety updates. No spam, ever.